Design [Regulatives / Guidelines]

posted by Pharma_88 – India, 2020-08-27 18:07 (938 d 01:08 ago) – Posting: # 21893
Views: 6,846

Dear All,

We are thinking to perform steady state BE study for XXX submission where Test product is ER formulation and Reference product is IR formulation. Further, Its HVD product. So, question is whether is this feasible to conduct replicate BE IR vs ER and if yes then what are the parameters for conclusion?

Thanks.

Complete thread:

UA Flag
Activity
 Admin contact
22,548 posts in 4,723 threads, 1,606 registered users;
23 visitors (0 registered, 23 guests [including 9 identified bots]).
Forum time: 18:15 CET (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5